Elounais Farah, Aburahma Ahmed, Alkotob Mohammad Luay, Al Hadidi Samer
Department of Internal Medicine, Hurley Medical Center, Flint, Michigan, USA.
Department of Cardiology, Hurley Medical Center, Flint, Michigan, USA.
BMJ Case Rep. 2017 Sep 27;2017:bcr-2017-221819. doi: 10.1136/bcr-2017-221819.
Fingolimod, a sphingosine-1-phosphate receptor modulator, is used for the treatment of relapsing-remitting multiple sclerosis. It is well known to cause bradyarrhythmias. We present a 63-year-old woman who was admitted to the hospital with sustained monomorphic ventricular tachycardia 2 weeks after fingolimod initiation. Further evaluation showed that the patient's ventricular tachycardia was most likely secondary to her medication. Medical practitioners need to be aware of such possible life-threatening side effects while using fingolimod.
芬戈莫德是一种鞘氨醇-1-磷酸受体调节剂，用于治疗复发缓解型多发性硬化症。众所周知，它会引起缓慢性心律失常。我们报告一名63岁女性，在开始使用芬戈莫德2周后因持续性单形性室性心动过速入院。进一步评估显示，患者的室性心动过速很可能继发于其所用药物。医生在使用芬戈莫德时需要意识到这种可能危及生命的副作用。
